Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.40 |
| ▸ | KLK7 | P49862 | 2/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.39 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.39 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.38 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25863476 | 0.92 | PSMB5 (0.44) | SIRT1SIRT2SIRT5KLK7KLK5 | |
| SCHEMBL25863358 | 0.81 | SIRT5 (0.52) | SIRT1SIRT2SIRT5PSMB5PSMB8 | |
| SCHEMBL21097237 | 0.79 | PSMB8 (0.49) | SIRT1SIRT2SIRT5PSMB5PSMB8 | |
| SCHEMBL18774075 | 0.79 | SIRT2 (0.50) | SIRT1SIRT2SIRT5KLK7KLK5 | |
| SCHEMBL18752309 | 0.78 | SIRT2 (0.49) | SIRT1SIRT2SIRT5KLK7KLK5 | |
| SCHEMBL21097238 | 0.78 | SIRT5 (0.49) | SIRT1SIRT2SIRT5PSMB5PSMB8 | |
| SCHEMBL12285322 | 0.76 | SIRT2 (0.49) | SIRT1SIRT2SIRT5PSMB5PSMB8 | |
| SCHEMBL18770780 | 0.74 | KLK7 (0.53) | SIRT1SIRT2KLK7KLK5 | |
| SCHEMBL18782520 | 0.74 | KLK7 (0.53) | SIRT1SIRT2KLK7KLK5 | |
| SCHEMBL18770781 | 0.74 | KLK7 (0.53) | SIRT1SIRT2KLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144799-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 | BICYCLETX LIMITED (GB) | 2023-05-11 | — | — | US | disclosed |
| US-20190184025-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 | BICYCLETX LIMITED (GB) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190184025-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 | EPHA2, EPHB2, ERBB2 | SIRT1 4761/4885SIRT2 4291/4885SIRT5 4536/4885 |
| US-20230144799-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 | EPHA2, EPHB2, ERBB2 | SIRT1 4761/4885SIRT2 4291/4885SIRT5 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.